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CHEMICAL PERMEATION ENHANCERS 
AND THEIR USE IN TRANSDERMAL DRUG DELIVERY 
FARIHA KHAN 
ABSTRACT 
The field of medicine has advanced such that we are now capable of combating many 
disorders through the use of carefully studied, well-developed therapeutics. There are a 
number of ways to administer such therapeutics including via inhalation, intravenously, 
orally, or transdermally. Of the aforementioned delivery pathways, transdermal drug 
delivery systems have gained much recognition for their ability to deter the premature 
metabolism of therapeutics as well as avoid potentially harmful side effects. But 
transdermal delivery systems come with their own set of challenges. For example, the 
topmost layer of the skin, the stratum corneum, serves as a sturdy rate limiting barrier to 
molecular permeation. Researchers have therefore sought out formulations that are able to 
temporarily and reversibly modify such barriers so that we may take advantage of the skin 
as a delivery route for necessary therapeutics. A number of chemicals, referred to as 
chemical permeation enhancers (CPE), have shown great promise in being able to do just 
that. CPEs have been proven to enhance drug flux without causing irreversible damage to 
the integrity of our skin’s natural barrier. This thesis will therefore explore the mechanisms 
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Despite significant advances in the field of medicine with respect to the 
development of potent therapeutics, one of the largest challenges faced by clinicians today 
is the efficient delivery of such medication with minimal side effects. The most common 
routes of drug delivery include intravenous (I.V.) injection, inhalation, oral delivery, and 
transdermal absorption. Each of the aforementioned delivery systems have their respective 
flaws and benefits. I.V. injections can deliver precise doses of medication quickly and 
effectively, which may be critical in emergency situations. But with such delivery systems, 
it becomes increasingly difficult to reverse or cease administration of a drug should an 
adverse reaction occur. I.V. delivery systems also lead to the systemic distribution of 
therapeutics making the likelihood of off-target side effects much larger than with other 
methods of delivery [1]. And yet the oft-quoted, largest downside to I.V. administration is 
the aspect of patient compliance. Patients that require repeat injections over the course of 
long periods of time may be deterred by the inconvenience and pain associated with I.V. 
administration, especially those with needle phobia. Inhalation shares the benefits of the 
I.V. route in that it can allow the efficient delivery of therapeutics, but it is limited in the 
number of diseases for which it can effectively administer medication. The oral route of 
delivery is most commonly employed for patients that require regular doses of medication. 
Though patient compliance is higher with oral delivery than it is with the I.V. route, there 
are still significant disadvantages to this system such as the first pass effect. When drugs 
are administered orally, they must transit the gastrointestinal (GI) tract before reaching 
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their target site. Throughout this transit, the drug is pre-maturely metabolized at multiple 
points leading to the delivery of a dose far less than what was initially administered. This 
decreased bioavailability forces clinicians to administer larger doses than would otherwise 
be required to reach efficacious plasma concentrations of the given therapeutic [2]. This, 
coupled with the fact that oral administration leads to systemic distribution of drugs, only 
heightens the likelihood of a patient experiencing the side effects associated with a given 
medication. And so, one is left to consider the use of transdermal drug delivery systems 
(TDDS). 
 
Since the beginning of time, people have applied balms and salves to their skin in 
an attempt to treat disease processes. In recent years, the science and technology behind 
the development of TDDS have improved significantly. Today, there are a number of drugs 
on the market that employ the use of transdermal absorption for both locally and systemic 
delivery of therapeutics. Such delivery systems hold significant advantages over alternative 
mechanisms of drug administration. First and foremost, it allows evasion of the first pass 
effect. Clinicians are therefore able to administer lower doses of a given therapeutic leading 
to the reduced potential for side effects. Patient compliance may also be higher with TDDS 
as application is non-invasive, painless and can be self-administered [3]. But as with any 
other delivery system, transdermal delivery has its fair share of disadvantages, the most 
significant of which is the difficulty associated with bypassing the natural barriers 
presented by the layers of the skin. 
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Structure and Function of the Layers of the Skin 
The skin is the largest organ within the human body. It serves an array of functions 
but first and foremost, it acts as a line of defense against exogenous dangers. The skin is 
able to block harmful ultraviolet (UV) radiation, pathogen infiltration, and chemical or 
mechanical injury. But it is this very defense-oriented functionality that makes the use of 
skin in transdermal delivery systems exceedingly difficult [4].  
 
The structure of the skin can be divided into three layers – the subcutaneous tissue 
(hypodermis) being the deepest layer, followed by the dermis, then the outermost epidermis 
(Figure 1) [5].  
 




The hypodermis connects the skin to the underlying fibrous tissue of the bones and 
muscles. It is well vascularized and mainly composed of fatty adipose and connective 
tissue. The function of this layer of the skin is to store fat and provide insulation. This latter 
function is inherently important as the body heavily relies on the skin for its role in thermal 
regulation [4].  
 
Following the hypodermis is the dermis which is composed of two distinct layers. 
The hypodermis is directly adjacent to the reticular layer of the dermis, which is composed 
of well-vascularized, thick connective tissue. This layer contains elastin fibers that 
contribute to the flexibility of skin and collagen fibers that bind water and allow the skin 
to remain hydrated. The reticular layer also houses a rich network of sensory nerves. The 
papillary layer adjacent to the reticular layer is composed of loose connective tissue, small 
blood vessels, fibroblasts, and a small amount of adipose tissue. The papillary layer also 
contains phagocytes which are defensive cells that aid in maintaining the immunological 
barrier the skin presents to external pathogens [4].  
 
The connective tissue of the papillary layer projects into the epidermis which is 
composed of five layers. The layers, from innermost to outermost, include the stratum 
basale, the stratum spinosum, the stratum granulosum, the stratum lucidum, and the stratum 
corneum (SC). The stratum basale contains active stem cells that undergo constant mitotic 
division. This layer produces new keratinocytes which are the building blocks of the skin. 
The keratinocytes continuously differentiate as they push up towards the outer layers of the 
epidermis. By the time the keratinocytes reach the SC they have already transformed into 
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dead, anucleated cells [6]. Despite this transformation, keratinocytes remain 
immunologically active and therefore play a role in the initial barrier our skin presents to 
any foreign substances. Secondary to cell injury, keratinocytes release pre-formed 
interleukin-1, a potent cytokine capable of setting off a proinflammatory response. 
Keratinocytes also increase the expression of cell adhesion molecules that ease the 
movement of other immunological cells such as Langerhans cells. Langerhans cells are the 
major antigen presenting cells of the epidermis and play a key role in subsequent T-cell 
migration and proliferation [7]. Together, the aforementioned cells, amongst others, 
maintain an immunological barrier to TDDS as they are prone to react to any foreign 
substances, including therapeutics. And yet, an immunological response is not the primary 
obstacle clinicians must overcome to deliver drugs transdermally.  
 
The primary barrier to transdermal drug delivery is of a structural nature. The 
composition of the outermost layer of the epidermis is comparable to a wall made of brick 
and mortar. The keratinocytes, referred to as corneocytes within the SC, resemble bricks 
that are filled with keratin bundles and surrounded by a protein-lipid cellular envelope. 
Transmembrane proteins, such as desmosomes and corneodesmosomes, strongly adhere 
adjacent corneocytes to one another. The mortar is represented by multiple lamellar layers 
composed of long chain ceramides, cholesterol, esters, and free fatty acids. This brick and 
mortar structure of the SC is developed over time as newly formed keratinocytes transition 
into corneocytes from the stratum basale to the stratum corneum of the epidermis [8], [9]. 
From a functional perspective, this structure is imperative to the SC’s ability to prevent 
water loss and defend the body against foreign substances. But like the immunological 
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barrier, this structural barrier hinders the absorption of potential therapeutics, especially 
those that are hydrophilic and of larger molecular weights. 
 
In order to surpass the barriers posed by the epidermis, researchers had to first 
understand potential paths of diffusion through the SC. There are three main forms of 
absorption via the SC: intercellular, intracellular, and transappendageal (Figure 2) [10].  
 
Figure 2: Visual representation of possible routes for surpassing the stratum corneum [10] 
Transappendageal transport includes passage through hair follicles, sweat glands, 
apocrine glands and nails. This form of transdermal delivery is appealing because it allows 
us to bypass the barriers presented by the SC while also providing the shortest pathway for 
drug delivery. The downside to this approach is that the surface area available for 
appendageal delivery is extremely limited, amounting to about 0.1% of the skin’s overall 
surface. An alternative pathway of diffusion would be transcellularly, straight through the 
SC. This pathway also poses difficulties due to the cellular envelope and lipid lamellae 
surrounding each corneocyte. Permeants utilizing this pathway would have to undergo 
multiple steps of partitioning while constantly alternating between the hydrophilic 
corneocytes and hydrophobic lipids. A third pathway available for transdermal delivery is 
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the intercellular route via the continuous lipid-rich matrix that surrounds the corneocytes 
[10], [11].  
 
The intracellular route is often considered the polar route of transdermal delivery 
as the corneocytes that make up a majority of this pathway are composed of hydrated 
keratin that provide an aqueous path for hydrophilic drugs. On the hand, the intercellular 
route, composed primary of lipids, is utilized for the diffusion of hydrophobic drugs 
through the SC [11]. Between these two pathways, the intracellular route is not considered 
the preferred path for dermal diffusion due to the very low permeability seen while passing 
through corneocytes and the obligation of the permeant to partition multiple times [12]. 
 
Despite being the major route of diffusion for most compounds, intercellular 
transport poses significant difficulties. The lipid lamellae that compose this pathway have 
alternating hydrophilic and hydrophobic components. The transport of large molecular 
weight drugs, especially those that are hydrophilic, becomes inherently difficult if the lipid 
bilayers remain intact [13]. In order to make transdermal diffusion a more viable route for 
drug administration researchers have developed a variety of mechanisms that allow the 
temporary and reversible alteration of the SC.  
Methods Used to Enhance Transdermal Absorption 
In recent years, multiple mechanisms have been developed to enhance the delivery 
of therapeutics through the SC. These include both physical and chemical methods of 
permeation enhancement. Chemical adjuvants include penetrating enhancers such as 
hyaluronic acid, peptides, and chemical permeation enhancers (CPEs), as well as 
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nanocarriers such as liposomes, biphasic vesicles, and microemulsions. Physical 
enhancement can be electrically driven with iontophoresis, electroporation, or ultrasound 
or attempt to bypass the SC all together via microneedles or jet needles. Bypassing the SC 
allows for increased delivery of macromolecular proteins which has proven to be difficult 
when using chemical adjuvants alone. Microneedles, for example, have become well 
established in clinical settings for the delivery of influenza vaccines and insulin. But one 
of the reasons transdermal delivery is so sought out is because it brings with it the promise 
of non-invasive drug delivery and thereby increased patient compliance. Despite its ability 
to delivery larger molecules, procedures such as those involving microneedles are still 
considered invasive [14].  
 
Noninvasive physical enhancers, such as ultrasound, are also effective in the 
delivery of macromolecules, but the extent of their efficacy is linked to the physiochemical 
properties of the molecule being delivered. For example, iontophoresis relies on the 
principles of electrical repulsion to push drugs through the SC. Therefore, this mechanism 
is far more effective with molecules that are electrically charged than those that are neutral 
[14]. Non-invasive physical enhancers also require complex, expensive machinery and 
experienced personnel to operate those machines. Such methods of enhancement therefore 
cannot be used to self-administer medication, another sought out advantage of TDDS.  
 
In comparison, chemical adjuvants do not require any machinery in order to carry 
out their effects. These formulations can be self-administered in a noninvasive, painless 
manner which may contribute to increased patient compliance [14]. The composition and 
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utility of chemical adjuvants are also comparatively cheaper than those of physical 
enhancers [3]. Of the aforementioned chemical adjuvants, chemical permeation enhancers 
in particular have been extensively researched and utilized for decades due to their ease of 
compositions and fairly low cost of production.  
 
CPE’s are mainly classified by their chemical structures. They can be used alone or 
in conjunction with one another. The mechanism of action of chemical enhancers mainly 
involves the temporary, reversible disruption of the SC. Ideally, a CPE will have the 
following characteristics [15]: 
1. nontoxic, non-allergenic, and non-irritating, 
2. pharmacologically inert, 
3. rapid-acting with predictable and reproducible activity, 
4. unidirectional, 
5. chemically compatible and easily formulated into a variety of systems, and 
6. cosmetically acceptable with suitable skin feel. 
There is not yet any one chemical enhancer with all six of the aforementioned 
characteristics. More so, the efficacy of most CPEs is almost always linked to worsening 
irritation of the skin [16]. A deeper understanding of the mechanistic behavior of such 
CPEs may allow researchers to find ways to overcome these undesirable side effects. In 








1. To discuss the mechanisms of action by which various chemical permeation 
enhancers act to increase the diffusion of drug molecules including: the push effect, 
the pull effect, fluidization of the lipid lamellae, and lipid extraction. 
2. To discuss the most prevalent chemical enhancers used in various transdermal 
delivery systems today including water, alcohol, fatty acids, Azone®, Transcutol®, 
terpenes, surfactants, etc. 
3. To discuss the possible side effects associated with chemical permeation enhancer 








CHEMICAL PERMEATION ENHANCERS – MECHANISMS OF ACTION 
 
Molecular permeation through the SC barrier can be considered in terms of 
diffusion through a passive membrane. The steady-state flux of a drug through the SC can 
be estimated by Fick’s second law of diffusion. Barry et al. derived the following simplified 
equation from Fick’s law: 
(Equation 1) 
where m is the mass of the permeant (the drug) that passes through the membrane in time, 
t; D is the diffusion coefficient of the permeant; C’0 is the concentration of the permeant in 
the formulation that coats the membrane; P is the partition coefficient of the permeant 
between the formulation and the membrane; h is the membrane thickness. Based on this 
equation, permeation enhancers may modify the flux of a drug through the stratum 
corneum in the following ways [17]:  
• By increasing the diffusion coefficient of the drug which can be achieved by 
disrupting the brick and mortar structure of the SC 
• By increasing the concentration of the drug in the formulation which can be 
achieved by incorporating an anti-solvent 
• By enhancing the partition coefficient between the formulation and the SC which 
can be achieved by improving the solvent nature of the SC 
• By thinning the SC barrier which would be unlikely. 
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Barry et al. proposed the Lipid-Protein Partitioning theory to classify the mechanisms 
by which chemical permeation enhancers can achieve the aforementioned modifications. 
These mechanisms fall under the following categories: disruption of the intercellular lipid 
lamellae, accumulation of CPE within the SC leading to increased partitioning of the drug 
formulation, or modification of the intracellular proteins within the corneocytes of the SC. 
Most chemical permeation enhancers act through a combination of these mechanisms in 
order to increase drug flux through the SC [11]. 
 
Modification of Intercellular Lipid Lamellae   
CPEs that act through modification of the lipid structure of the SC can increase 
drug flux by disrupting the lamellar and lateral organization of intercellular lipids. This 
mechanism subsequently increases the diffusion coefficient, D, of the permeant (Equation 
1) [17]. In terms of the lamellar organization of the SC lipids, Lane et al. describes three 
primary sites of disruption: interaction with the polar head groups of ceramide (A), 
interaction with the hydrophilic region of the lipid bilayer (B), and interaction with the 
hydrophobic region containing lipid alkyl chains (C) (Figure 3) [18]. 
 
Figure 3: Potential sites of action within the lipid bilayer of the SC. Adapted from Lane et al 2012 [18] 
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In terms of lateral organization of the SC, intercellular lipids can exist in three phases: 
orthorhombic (OR), hexagonal (HEX) or liquid-crystalline (LIQ). In the orthorhombic 
phase the lipid chains exist in an all-trans conformation and are organized in a rectangular, 
crystalline lattice. This is the densest of the three phases. In the hexagonal phase the lipid 
chain conformation is tilted and organized in a hexagonal lattice. This phase is less dense 
compared to the OR phase. In the liquid-crystalline phase the lipid chains exhibit gauche 
isomerization and show no lateral organization (Figure 4) [19].  
 
Figure 4: Molecular organization of the SC lipids in the OR, HEX, and LIQ phases. Characteristic IR features 
of the three phases are shown in the CH2 symmetric stretching (top row) and the CH2 scissoring (bottom row) 
regions of their second-derivative spectra. Adopted from Boncheva et al. 2008. [19]. 
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A study using Attenuated Total Reflectance - Fourier Transform Infrared (ATR-
FTIR) spectroscopy has shown that human SC lipids are organized predominantly in the 
OR phase, although all three phases coexist. The results of this study showed that CPE’s 
can shift the lateral organization of the SC from an ordered OR phase to a highly disordered 
LIQ phase by incorporating into the lipid bilayer. The resulting phase transition leads to 
increased drug flux [19]. The transition from one phase to another has also been observed 
to occur in a temperature dependent manner. Higher temperatures correspond to an increase 
in the LIQ phase of lipid organization [20]. Some CPEs have been seen to act by shifting 
the temperature at which phase transitions may occur. These CPEs enhance drug flux by 
promoting phase transitions at lower temperatures [21]. 
 
As discussed above, an alternate mechanism of lipid modification is via interactions 
with the polar head groups of ceramides (site A from Fig. 3). Under normal conditions, the 
ceramides found in the lipid lamellae are closely interconnected via strong hydrogen bonds 
between amide I groups from adjacent ceramides. These hydrogen bonds strengthen and 
stabilize the lipid bilayer, largely contributing to the barrier property of the SC. Jain et al. 
showed, using Fourier Transform Infrared (FTIR) studies, that CPEs with more 
electronegative groups than the amide I group of the ceramide, i.e. an alcoholic -OH group, 
can compete with the ceramide head for hydrogen bond formation. When such CPEs enter 
the lipid bilayer, they disrupt the existing hydrogen bonding amongst the polar ceramide 
heads. This destabilizes the lipid bilayer leading to lipid fluidization and increased drug 
flux [21]. More recently, Kontogiannidou et al. studied the effects of sesquiterpenes on SC 
lipids. Their differential scanning calorimetry (DSC) and ATR-FTIR studies showed that 
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sesquiterpenes also caused lipid detachment which resulted in lipid fluidization and 
increased permeation through the SC lipid bilayer [22]. 
 
“Pooling” of CPEs in the hydrophobic and hydrophilic regions (sites B and C in 
Figure 3) of the SC lipid bilayer has been considered another common mechanism of 
increasing drug flux. Janusova et al. used IR spectroscopy to study the interactions between 
CPEs and SC lipids. They found that the CPE L-Pro2 acted by incorporating into the SC 
and forming a separate liquid ordered domain within the lipid bilayer. This “pooling” of L-
Pro2 led to a temporary defect in the skin lipid barrier, opening up a more permeable 
pathway for molecular diffusion [23]. Naik et al. reported similar findings of phase 
separation when studying the effects of oleic acid (OA) on SC intercellular lipids using 
ATR-IR. This study showed that OA exists in a fluid state in the SC while the surrounding 
endogenous lipids exist in a disordered state within the superficial layers and in an ordered 
state within the deeper layers of the SC. They attributed the permeation enhancement of 
OA to the formation of this fluid state amidst the solid and fluid lipid domains of the SC 
[24]. This mechanism of incorporation by CPEs has a two-fold effect. It increases the drug 
partition coefficient (P in Eq. 1) and it modifies the solvent properties of the SC such that 
increased drug partitioning into the SC is favored [25].  
 
Lipid extraction by CPEs may also increase drug permeation. Sugibayashi et al. 
used ATR-FTIR to study the effects of solvents like ethanol (EtOH) on SC lipids. This 
study showed that EtOH pretreatment of skin led to the extraction of lipids decreasing the 
permeation pathway for lipophilic drugs. This mechanism decreased resistance to 
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molecular permeation [26]. Mendenha et al. used electron paramagnetic resonance (EPR) 
spectroscopy to show similar effects of terpenes on 1,2-dipalmitoyl-sn-glycero-3-
phosphocholine (DPPC) model membranes. Their studies showed that terpenes led to the 
extraction of spin-labeled lipids of the SC [27]. In previous studies using FTIR, this 
mechanism of lipid disruption was attributed to the subsequent increase in permeation of 
luteinizing hormone releasing hormone through porcine skin [28]. According to Karande 
et al., the potency of a molecule to utilize lipid extraction as a mechanism of action is 
intrinsically linked to its ability to form intermolecular ionic interactions, especially 
hydrogen bonds. The ability to form hydrogen bonds originates from highly 
electronegative atoms such as sulfur, nitrogen, or oxygen. Therefore, CPEs with such 
components will be able to compete with the polar head groups of intercellular lipids to 
form hydrogen bonds. Formation of hydrogen bonds by CPEs can then weaken the lipid 
bilayer through lipid extraction leading to a subsequent increase in drug flux [29]. 
 
Modification of Intracellular Corneocytes 
Multiple studies have shown that most drugs applied to the skin diffuse across the 
intercellular lipid pathway of the SC [30], [31]. But the bulk composition of the SC (70-
95%) is made up of intracellular proteins found within corneocytes, so the role of the 
intracellular pathway in transdermal drug delivery must also be considered [31]. 
Crosslinked soft keratin constitutes a majority of the protein content found within 
corneocytes. The keratin bundles that fill corneocytes are highly hydrated and exist mainly 
in an a-helix conformation. Certain CPEs, especially those that retain H-bonding 
capabilities, have been seen to interact with intracellular keratin. Anigbogu et al. studied 
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the effects of dimethyl sulfoxide (DMSO) on SC via Fourier Transform (FT) Raman 
spectroscopy. They found that DMSO tends to absorb into corneocytes and alters the 
conformation of intracellular keratin from a-helices to b-sheets. They postulated that this 
resulted in a more permeable structure of the SC, leading to increased drug flux [25]. More 
recent studies have also reported interactions amongst CPE’s and intracellular keratin. 
Hatta et al. used small-angle and wide-angle x-ray diffraction (SAXD and WAXD, 
respectively) to study the uptake of ethanol into the SC. They found that ethanol penetrates 
into corneocytes and partially disrupts the structure of the soft keratin found within it. In 
this way ethanol is able to form routes through which hydrophilic molecules can permeate 
the SC [32]. Water is a commonly used CPE. Though its exact mechanism of action is 
unclear, it has been noted that an increase in the hydration level of the SC will generally 
lead to an increase in drug flux [30]. A study by Bouwstra et al. showed that at hydration 
levels of 57 %-87% wt/wt, water accumulation is only observed in the intracellular, central 
regions of the SC [33]. The fact that water applied to the SC is mainly taken up by 
corneocytes again suggests that being able to affect the intracellular pathway may also 
contribute to the mechanism of CPEs.  
 
Indirect Mechanisms of Enhanced Diffusion 
There are notable ways in which CPEs have been seen to increase drug flux that 
are not directly correlated with modification of the SC structure. Two such mechanisms 




Figure 5: CPE "Push" and "Pull" Mechanisms of Action. Adapted from Haque et al. 2018. [5] 
The pull effect is considered as a mechanism of action when a close relationship is 
noted between the rate of excipient and the rate of solute permeation. According to this 
effect, some CPEs have the ability to pull molecules with them as they cross the SC barrier. 
One example of this mechanism in action was studied by Dai et al. through the use of 
coarse-grained molecular dynamic (CG-MD) simulations. Borneol, utilized as the CPE, 
was seen to first directly weaken the lipid bilayer by destroying the hydrogen bond network 
of the polar heads. It was then seen to pull the osthole molecules (the drug) with it as it 
permeated into the hydrophobic tail regions of the lipid bilayer. According to this study, 
the pull effect was the main mechanism behind increased permeation of osthole into the 
SC during the first 100 ns of the study [34]. Similar findings were previously reported by 
Heard et al. who showed the ability of ethanol and 1,8-cineole to pull molecules of 
mefenamic acid with them as they permeated the SC barrier. Because there was found to 
be a close connection between the rates of enhancer and solute permeation, the authors 
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stated that, in this case, the pull effect sufficiently accounted for the permeation 
enhancement mechanism of ethanol and 1,8-cineole [35]. 
 
There are two mechanisms of action by which a formulation can act to “push” a 
drug into the skin. The first would be to increase the thermodynamic activity of the drug 
such that it is more likely to permeate the SC. This can be achieved by choosing a CPE that 
will itself quickly diffuse into the SC. This will increase the concentration of the solute in 
the donor phase, leaving it with excess free energy. The excess free energy will then push 
the drug down a favorable concentration gradient into the SC [36]. The push effect may 
also be achieved by choosing a drug and CPE combination that have minimal affinity for 
one another. If the solubility parameters between the drug and the CPE are sufficiently 
different, the attraction of the drug towards the CPE will be low. This will allow the drug 
to easily escape the formulation and diffuse into the skin [5].  
 
A third indirect mechanism by which CPEs can increase drug flux is by solubilizing 
the drug within the formulation. Surfactants are examples of potent CPEs that act via this 
mechanism. They are able to solubilize a permeant by forming micelles which in turn eases 
the diffusion of the permeant into the SC [37]. This mechanism is especially important for 
drugs that would otherwise exhibit low solubility within the layers of the SC. The ability 
to solubilize a permeant has been associated with the mechanisms of both the push effect 
and the pull effect. Some studies have found that when a CPE solubilizes drug molecules 
within a formulation, it increases the concentration of the drug in the donor phase. This 
creates a concentration gradient that favors the movement of the drug into the SC. This 
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description aligns closely with the push effect and is described as such by Mura et al. [38]. 
A previous study by Kadir et al. attributed the solubilization of the permeant in the 
formulation to the pull effect. This study proposed that solubilizing the drug within the 
formulation allowed the CPE to drag the permeant with it as it diffused into the SC [36]. 
Despite which umbrella term the solubilization of a permeant falls under, it has been well 
established as a potent mechanism for increasing drug flux.   
 
Though examples of specific CPEs have been associated with each mechanism 
described in this section, most studies have found that CPEs rarely act through just one 
mechanism. Rather, most CPEs employ a combination of multiple mechanisms in order to 
carry out their effects. For this reason, CPEs are usually categorized by their distinct 
structural properties rather than their mechanisms of action [30]. The following section will 
follow this trend in summarizing the most prevalent CPE’s used in transdermal delivery 











CHEMICAL CLASSES OF PERMEATION ENHANCERS  
 
There are a large number of chemicals to date that have been identified as potent 
transdermal permeation enhancers. Due to their varied mechanisms of action, these CPEs 
are categorized based on similarities in their chemical structures. Although it is far from a 
complete list, a few of the major chemical classes of CPEs that will be discussed throughout 
this paper are listed in Table 1 [30]. 
Chemical Class Enhancer 







Propylene glycol (PG) 
Amides Cyclic amides 
Azone® (1-dodecylazacycloheptan-2one or 
laurocapram 
Fatty Acids Lauric acid  
Oleic acid  
Linoleic acid 
Ether alcohols Transcutol® (diethylene glycol monoethyl ether) 
Surfactants Anionic surfactants  
Sodium lauryl sulphate (SLS) 
Cationic surfactants 
Benzalkonium chloride  
Cetylpyridinium chloride 
Nonionic surfactants 















Although it is not listed as one of the classes of CPEs, water is the most common 
and safest way to increase the transport of drugs across the SC. At baseline, the water 
content of the SC is usually 5-10% but this can be increased beyond 50% in occlusive 
conditions [5]. Alonso et al. used electron spin resonance to study the effects of different 
hydration states on the permeability of the SC. Their results showed that membrane fluidity 
increased with increased water content in neonatal rat SC. The increase in fluidity was 
noted to be larger near the polar head groups of the lipid lamellae. The proposed mechanism 
behind this lipid fluidization was the formation of small hydration shells through hydrogen 
bonding by water molecules. This in turn enlarged the free space for segmental motion of 
the first carbons of the lipid acyl chains. Due to the low fluidity of this area, penetration 
through the region of the first carbon of the acyl chain is otherwise considered the rate 
limiting step of water transport [39]. The results of this study were complemented by those 
of Denda et al. who analyzed changes in the SC of hairless mice maintained at a high 
relative humidity (RH > 80%) vs low humidity (RH < 10%) environment for two weeks. 
The study found that when kept in a low humidity environment, the number of layers of 
the SC, the total concentration of SC lipids, and the overall thickness of the epidermis 
increased significantly [40]. The morphological changes to the SC seen in low hydration 
circumstances may further explain the potency of water as a CPE. 
 
Later studies found that occlusion by water molecules increases drug flux by 
diffusing into intracellular corneocytes and causing them to swell. According to Zhai et al., 
increasing skin hydration also led to increased skin temperature (from 32°C to 37°C). The 
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same study detailed a ‘reservoir effect’ of hydration. Under occlusive conditions, drug flux 
into the SC was increased. Once the occlusive dressing was removed, the SC dehydrated 
and movement of the drug slowed, thereby creating the reservoir of the permeant in the SC 
[41]. Though the exact mechanism of action of water as a CPE is still debated, it remains 
one of the oldest and safest ways to increase drug flux through the SC. 
 
Alcohols 
Alcohols are commonly used by transdermal drug delivery systems to enhance drug 
flux. They are organic molecules characterized by the presence of one or more hydroxyl 
groups (-OH) attached to a hydrocarbon chain [42]. There are three main chemical 
variations amongst alcohols utilized as CPEs. They can be classified as long-chained/fatty 
alcohols (containing a longer hydrocarbon chain), short-chained alcohols, or glycols 
(containing two hydroxyl groups). Alcohols can act through various mechanisms of action. 
The highly electronegative oxygen atom found in hydroxyl groups allows alcohols to act 
via lipid fluidization and lipid extraction. Alcohols have also been recognized as potent 
solvents, which may allow them to increase drug partitioning by changing the solubility of 
the drug in the SC or increase the thermodynamic activity of the drug in the donor phase 
[30].  
 
Chandra et al. studied the effects of multiple alcohols (ethanol, n-propanol, 
isopropyl alcohol (IPA), n-pentanol, n-butanol, and propylene glycol (PG)) on the 
permeation of ketorolac through rat skin. The study found that smaller chained alcohols, 
such as IPA or ethanol, were more efficient at enhancing dermal permeation. It was 
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theorized that as solvents, alcohols extracted lipids from the SC which resulted in reduced 
lag time of diffusion and overall increased diffusivity of the permeant [43]. Many other 
studies have also described the efficacy of ethanol as a solvent or cosolvent in transdermal 
delivery systems. Haq et al. found that ethanol solvents, when used as a vehicle for 
Thymoquinone (TQ) diffusion, increased the capacity of the SC for TQ uptake. They stated 
that via the “pull” effect, ethanol was more effective than Tween 80, N-M ethyl 
pyrrolidone, Azone®, Transcutol®, and oleic acid in solubilizing and dragging TQ 
molecules with it into the skin membrane [44]. Megrab et al. studied the efficacy of ethanol 
as a cosolvent used to increase the permeation of Oestradiol (OE) into the SC from a drug-
saturated ethanol/water system. They found that the effects of ethanol on OE permeation 
were concentration dependent. At first, OE flux increased with increased concentrations of 
ethanol. At low concentrations of ethanol, the mechanism of increased flux was correlated 
to ethanol increasing the solubility of OE within the SC. At higher concentrations of 
ethanol, lipid fluidization was said to be its main mechanism of action. Interestingly, there 
was also found to be a concentration dependent limit to the efficacy of ethanol. Ethanol’s 
optimal concentration range was found to be between 40% – 60% wt / wt. Once ethanol 
reached concentrations greater than 60% wt / wt, a decrease in OE flux was observed. The 
study postulated that at concentrations above 60%, ethanol may remove water from the SC. 
Because increased flux has been correlated with increased hydration of the SC, this 
dehydration was postulated to cause the decreased flux of OE [45].  
 
Long chained fatty alcohols have also been shown to be effective permeation 
enhancers for multiple drugs [46]. Kandimalla et al., studied the effects of saturated and 
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unsaturated long chained, fatty alcohols in increasing melatonin diffusion through the SC. 
A biphasic flux of melatonin was observed secondary to the addition of both saturated and 
unsaturated fatty alcohols (SAFL and USFAL, respectively). For both fatty alcohols, 
melatonin flux was seen to increase with increased chain length in the first phase of 
permeation but the mechanism behind this increased flux varied. For SFAL, the mechanism 
was mediated by accumulation within the SC lipid bilayer leading to increased 
solubilization and lipid extraction. Interactions between USFAL and SC lipids were more 
difficult because most of the lipids in the SC are saturated. Therefore, USFAL increased 
permeation by inserting itself into the SC lipid packing and disrupting its order and stability 
due to its kinked structure. In the second phase, a decrease in melatonin flux was noted 
with increased chain length. It was theorized that drastic modifications of the SC due to 
ongoing effects of fatty alcohols led to the diffusion of polar components from the applied 
formulation. These components then brought the polarity of the skin closer to that of the 
formulation leading to reduced formulation/skin partitioning of melatonin [47]. 
Kanikkannan et al. studied the effects of SFAL on melatonin diffusion across hairless rat 
skin. Their study found that maximum efficacy of SFAL was dependent on its chain length 
with decreased permeation seen at chain lengths increased beyond ten carbons [46]. These 
findings were supported by similar correlations between chain length and enhancer efficacy 
seen when studying the effects of SFAL on the diffusion of naloxone through human skin. 
The difference with this study was that greatest efficacy was seen with twelve carbon chain 
lengths [48]. Effective chain lengths of 10-12 carbons correspond to the chain length of the 
steroid nucleus of cholesterol. It was therefore suggested that the link between carbon chain 
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length and enhancer efficacy was due to CPE disruption of ceramide-cholesterol or 
cholesterol-cholesterol interactions within the SC [46]. The efficacy of long chained fatty 
alcohols is therefore considered to be dependent on both carbon chain length and timespan 
of application. 
 
The most common glycol used as a CPE in TDDS is propylene glycol [30]. PG has 
been used in transdermal formulations since 1932, both individually as a chemical enhancer 
and as a cosolvent or vehicle for increased permeation. Though multiple mechanisms have 
been proposed, the exact mechanism of action of PG is still unclear [12]. The effects of PG 
on the diffusion of estradiol and metronidazole through excised full thickness human skin 
was studied [49]. Here, PG was seen to enhance permeation of both drugs by acting as a 
solvent vehicle, i.e. by carrying the drug with it as it diffused into the SC. This mechanism 
closely resembles what is now considered the “pull” effect. The effects of PG were also 
studied via small-angle X-ray scattering (SAXS) and differential thermal analysis (DTA). 
According to the results of this study, PG was able to enhance drug flux by incorporating 
into the polar head regions of the intercellular lipid bilayer and increasing its interfacial 
area. Additionally, this study found that application of PG led to a decrease in the transition 
temperature required for changes in the lateral organization of intercellular lipids [50]. 
Pudney et al. monitored the penetration of trans-retinol secondary to the addition of PG in 
vivo using confocal Raman microspectroscopy. They found that the depth of permeation 
of trans-retinol was directly correlated with the depth of penetration of PG. They stated 
that PG may decrease the polarity of the aqueous regions of the SC to insert itself within 
the lipid bilayer. Accumulation of PG within the SC may then lead to increased partitioning 
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of the permeant [51]. A study employing the use of ATR-FTIR found that PG could 
successfully enhance the diffusion of phenols across the SC. The mechanisms of action 
observed in this study included dehydration of keratin within corneocytes and lipid 
extraction leading to a change in the solubility properties of the SC. Notably, this study 
disputed previous claims that PG enhanced diffusion through a carrier mediated effect. 
This claim was made secondary to findings that showed that the amount of phenol carried 
into the SC by PG was minute compared to the amount that diffused independently. Rather, 
they stated that the main mechanism behind the increased flux by PG was due to its ability 
to change the solubility profile of the SC towards one more favorable to the diffusion of 
phenols within intercellular lipids of the SC [52]. Carrer et al. more recently studied the 
effects of PG on the permeation of hydrophilic and hydrophobic drugs through pig skin 
using Franz diffusion cells. They found that although PG could increase the permeation of 
all permeants tested, it showed greatest efficacy in increasing flux of hydrophilic 
molecules. They attributed this effect to PG’s ability to modify the skin lipidic barrier. 
Their study also analyzed the effects of PG via µFTIR. Their results supported previous 
findings reporting PG’s ability to alter the lipidic order of the bilayer to a more disordered 
lateral organization. Interestingly, they found this effect of PG stretched beyond the 
epidermis to the dermal layers of the skin [12]. Although the exact mechanism of PG is 









Azone (1‐dodecylazacycloheptan‐2‐one or laurocapram) was the first synthetically 
prepared transdermal penetration enhancer, initially patented in 1976. It falls under the 
chemical category of amides and is composed of a polar head group joined to a twelve-
carbon aliphatic chain. This hydrocarbon chain makes Azone highly lipophilic. Despite 
this attribute, Azone has proven to be effective at enhancing the penetration of both 
hydrophobic and hydrophilic drugs through the SC. Similarly, the molecular weight of a 
drug does not seem to hinder the efficacy of Azone with enhancements seen of both small 
and large molecular weight molecules. At room temperature, Azone exists as a clear, 
odorless liquid. When applied to the skin, Azone appears smooth and oily without leaving 
behind a greasy residue [53], [54]. Such properties make this CPE especially favorable for 
use in topical formulations.  
 
Stoughton et al. found that, like alcohol, the effects of Azone are also concentration 
dependent. Interestingly, Azone was found to be most effective when used in lower 
concentrations with decreasing efficacy as concentrations were increased [54]. Initial 
studies found the optimal concentration of Azone to be between 2-10%, but more recent 
studies have found that Azone works best between concentrations as low as 0.1-5%. The 
concentration of Azone required for optimal enhancement of the permeant varies from drug 
to drug. The efficacy of Azone is also dependent on the formulation within which it is used. 
Azone was found to be insoluble in water, but soluble in most organic solvents with the 




Although Azone has been studied extensively since its initial discovery, its exact 
mechanism of action is still under investigation. Various mechanisms have been proposed 
to understand the efficacy of Azone as a CPE. The most supported theory is that Azone 
exerts its effect by interacting with the lipid domain of the SC. Hadgraft, et al.  proposed 
that, because of its large polar head group and lipophilic chain, Azone is able to 
heterogeneously partition into the lipid bilayer and disrupt its lamellar packing arrangement 
[55]. This theory is supported by the idea that Azone can exist in a bent “soup spoon” 
conformation with the ring in its head group arranged at an angle to its lipophilic chain 
(Figure 6). 
 
Figure 6: Conformations of Azone. Only 8 chain hydrocarbons shown. Adapted from Hadgraft et al. 1996 [55] 
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As can be seen in Figure 6, the bent spoon conformation has a higher energy of 6.1 kcal in 
comparison to the non-bent conformation energy of 5.2 kcal. This energy difference of 
about 1 kcal corresponds to a high probability of 0.2 for the existence of the “bent spoon.” 
It was proposed that the increased energy of this bent conformation is compensated by the 
removal of hydrophobic ring methylene groups from the polar head region of the lipid 
bilayer [55]. Hadgraft et al. argued that the ceramide molecules packed into the bilayer 
structure would resist the existence of this higher energy formation of Azone. 
Alternatively, they proposed that after partitioning into the lipid bilayer, Azone competes 
for the hydrogen bonding sites between ceramide head groups. Because it is widely 
accepted that the hydrogen bonds between ceramide molecules stabilize the lipid structure 
of the SC, it was concluded that disrupting these bonds allowed Azone to enhance 
partitioning of drugs within the SC [55]. Pham et al. studied the effects of Azone on intact 
porcine SC organization via natural abundance 13C polarization transfer solid-state nuclear 
magnetic resonance (NMR). This method allowed them to detect small changes in the 
mobility of the minor fluid and major solid components of the SC under various hydration 
levels. They found that with high water content, Azone led to increased mobility in the 
ceramide headgroups of the SC. This is consistent with the idea  that despite what the exact 
interactions may be, Azone likely partially acts through modifications of the polar region 
of the SC lipids [56].  
 
Pilgram et al. suggested that the mechanism of action behind Azone’s efficacy lies 
in its ability to intercalate within the lateral arrangement of the SC lipids. They studied the 
interactions between Azone and lipids isolated from human SC via electron diffraction 
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(ED). Their results showed that upon addition of Azone, separate fluid domains formed 
between SC lipids, while the orthorhombic lipid organization surrounding these domains 
remained locally present. It was suggested that between these separate fluid domains, new 
penetration pathways may arise which then result in increased permeability [57]. 
Additionally, via NMR studies, Pham et al. found that these segregated fluids domains 
dissolved small amounts of SC lipids further contributing to increased molecular mobility 
in the headgroups and chains of SC lipids. Though it is clear that Azone acts by disrupting 
the lipophilic region of the SC, it was not found to exert an effect on the protein structures 
within the SC [56]. 
 
Terpenes and Essential Oils 
Terpenes are non-aromatic compounds composed only of carbon, hydrogen, and 
oxygen atoms. They are naturally occurring substances that are primarily extracted from 
vegetable oils, but also found in a number of well-known essential oils such as eucalyptus, 
chenopodium, and ylang ylang. Due to the aforementioned properties terpenes have long 
been used as flavorings, perfumes, and medications [17], [27].  
 
The chemical structure of terpenes is based on repeated isoprene units (C5H8) and 
depending on the number of these units, they can be categorized as either monoterpenes	
(C10), sesquiterpenes (C15) or diterpenes (C20). Furthermore, they can be classified by the 
chemical groups attached to them such hydrocarbons, alcohols, oxides, ketones, or esters. 
The ability of a terpene to effectively enhance permeation depends on its chemical structure 
and on the drug being applied [30]. Barry et al. studied the effects of seventeen simple 
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cyclic terpenes (varied based on the chemical groups attached to them i.e., hydrocarbons, 
alcohols, ketones, oxides) in enhancing permeation of the model hydrophilic drug, 5-
fluorouracil (5-FU). The permeation experiments performed on excised human epidermal 
membranes found that alcohol and ketone terpenes were more effective than hydrocarbon 
terpenes in enhancing penetration of 5-FU. Within the subgroup of oxides, the study found 
that cyclic ethers were more effective that epoxides in enhancing diffusion [58]. Zhu et al. 
used skin electrical resistance (SER) to investigate the effects of seven oxygen-containing 
terpenes on the SC structure. Their studies showed that cyclic terpenes such as 1,8-cineole, 
terpinen-4-ol, menthol and alpha-terpineol possess higher enhancement ratio (ER) values 
compared with linear terpenes such as linalool, geraniol and citral. These results were 
supported by ATR-FTIR analysis which revealed that the effect of cyclic terpenes on the 
SC lipid arrangement was stronger than that of linear terpenes [59]. 
 
Studies have shown that the effects of terpenes are also highly dependent on their 
lipophilicities. For example, oxygen-containing polar terpenes (carvacrol, menthol) have 
been found to be more potent at increasing permeation of hydrophilic drugs and 
hydrocarbon monoterpenes (limonene, p-methane) have been found to be more potent at 
increasing permeation of lipophilic drugs [15]. The aforementioned studies conducted by 
Barry et al. support these findings in that permeation of hydrophilic 5-FU was found to be 
most enhanced by hydrophilic alcoholic and ketone terpenes [58]. Tas et al. studied the 
effects of various terpenes (anethole, carvacrol, and menthol) on the permeation of the 
highly lipophilic anti-inflammatory drug, Etodolac. Their ex vivo permeation studies on 
excised rat skin revealed that the hydrophobic terpene, anethole, most significantly 
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enhanced the absorption of etodolac. In contrast, hydrophilic terpenes, menthol and 
carvacrol, did not enhance the absorption of etodolac [60].  
 
Like most CPEs, various mechanisms of action have been associated with terpenes. 
Barry et al. referred to the LPP theory in describing the mechanism of action behind the 
terpenes studied throughout their experiments. It was proposed that terpenes act in part by 
modifying intercellular lipids while having little effect on intracellular proteins found 
within corneocytes. Furthermore, terpenes were not seen to increase partitioning of 5-FU 
within the SC as expected due to the poor solubility of 5-FU in most terpenes [58]. 
Narishetty et al. found similar results in studying ex vivo permeation of hydrophilic 
zidovudine (AZT) across rat skin secondary to the addition of terpenes. Terpenes were not 
seen to alter the SC/vehicle partition coefficient of AZT or the thermodynamic activity of 
the drug in the donor formulation. Alternatively, a significant reduction in activation 
energy for AZT permeation was noted secondary to the addition of cineole. This reduced 
energy indicated disruption of the intercellular lipid bilayer. It was proposed that the 
molecular mechanism of this disruption may be due to the preferential hydrogen bonding 
of monoterpenes with ceramide head groups. These bonds break the lateral/transverse 
hydrogen bond networks of the lipid bilayer creating new polar pathways within 
interlamellar regions of the SC. This effect was further substantiated by molecular 




Figure 7: Representation of the effect of terpenes on the SC lipid bilayer. Terpenes are shown to break 
transverse hydrogen bonds leading to wider aqueous regions near polar head groups of adjacent lipid lamellae. 
Adopted from Narisheety et al. 2004 [61]. 
Later studies by Narishetty et al. employed the use of ATR-FTIR and DSC to assess 
the effects of 1,8-cineole and L-menthol on phase behavior of SC lipids and permeation of 
AZT across human cadaver skin. Their results showed that both terpenes enhanced 
permeation of AZT by increasing the hydration levels of the SC lipid system through the 
formation of new aqueous channels. A reduction of lipid phase transition temperatures was 
also noted which led to a transformation of the lateral organization of SC lipids from its 
highly ordered OR packing to a less ordered HEX packing [62].  
 
Kontogiannidou et al. studied the effect of chemically synthesized sesquiterpenes 
on the permeation of macromolecule fluorescein isothiocyanate-dextran 4 kDa (FD-4) 
across full thickness human skin. Their ATR-FTIR study showed that increased permeation 
secondary to the addition of sesquiterpenes could be attributed to lipid extraction. These 
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results were supported by subsequent DSC studies where shifts to lower endothermic peak 
temperatures signified lipid disruption and detachment of lipids from the SC [22]. Lan et 
al. found similar results when studying the effects of Z. bungeanum oil (an essential oil), 
limonene, terpinen-4-ol, and 1,8-cineole on permeation through rat abdominal skin. Their 
FTIR studies showed that the tested CPEs increased drug flux by perturbing and extracting 
SC lipids [63]. 
 
Despite initial claims against interactions between terpenes and intracellular 
proteins, recent studies have shown that such interactions may exist depending on the 
terpene applied. DSC studies by Kontogiannidou et al. revealed detachment of proteins 
from the SC secondary to the addition of sesquiterpenes [22]. Molecular modeling and 
ATR-FTIR studies done by Zhu et al. provide further evidence of interactions between 
terpenes and skin proteins. Their results show that terpenes such as 1,8-cineole interact 
with intracellular keratin through van der Waals forces and hydrophobic interactions 
subsequently allowing terpenes to interfere with the interactions between water and keratin. 
But despite these findings, Zhu et al. maintained that the main mechanism promoting the 
actions of terpenes were those mediated by disruption of the SC lipid organization [59]. 
 
Joshi et al. provides a rather unique mechanistic effect of the terpene, menthol. 
Desmosomal adhesion proteins are known to restrict paracellular transport through the SC 
by promoting the close packing of corneocytes. In order to function, desmosomes require 
calcium-dependent cadherin as high extracellular calcium induces cadherin mediated cell-
cell adhesion. Menthol is known to trigger the Transient Receptor Potential channel (TRP) 
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TRPM8 which mediates calcium entry into the cell, lowering extracellular calcium 
concentrations. In-vivo microdialysis studies showed that menthol’s ability to increase 
drug permeation was significantly hindered when a calcium channel blocker was added to 
the formulation. Based on these results, Joshi et al. proposed that menthol physiologically 
increased percutaneous penetration by decreasing cadherin modulated cell-cell adhesion 
through interactions with the TRPM8 channel. They stated that these results may serve to 
complement the accepted concept that menthol acts by interfering with the lipid 
arrangement of the SC in order to increase its fluidity and thereby drug flux [9]. 
 
Fatty Acids 
Fatty acids (FA) are characterized as amphiphilic molecules due to their nonpolar 
hydrocarbon chain and a polar terminal carboxylic group. The general formula for a fatty 
acid is –CH3(CH2)nCOOH. FAs may exist in a saturated (containing only single bonds) or 
unsaturated form (containing double or triple bonds). Depending on the arrangement of 
their double bonds, unsaturated FAs may exist in a cis or trans configuration. The 
effectiveness of FAs as CPEs has been found to depend on their degree of saturation, chain 
length, and structure [64].  
 
By studying permeation profiles of melatonin through rat skin, Kandimalla et al. 
found that saturated FA’s showed continued increases in permeation of melatonin when 
the chain lengths were increased from 9 to 10 and from 10 up to 12 carbons. Decreased 
permeation of melatonin was seen when chain lengths were increased beyond 12 carbons. 
These finding were in close correlation with the previous reports stating the optimal chain 
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length for saturated FAs to be between 10-12 carbons. It was proposed that increasing the 
chain length of the hydrocarbon group beyond 11 carbons may increase the lipophilicity of 
the molecule which would then increase their affinity towards SC lipids. This increased 
affinity may slow the permeation of FAs and subsequently the flux of melatonin. 
Alternatively, FAs with less than 10 carbon atoms are not lipophilic enough to sufficiently 
partition through the skin which then slows the permeation of melatonin. For unsaturated 
fatty acids, an 18-carbon chain length and cis double bond conformation was found to be 
optimal for increasing drug flux. It was also found that increasing the number of double 
bonds in unsaturated fatty acids generally increased the diffusion of melatonin through rat 
skin. But contradicting results were seen in studies utilizing porcine skin where an increase 
in the number of double bonds in unsaturated FAs lead to a decrease in permeation. These 
findings are note-worthy as permeation through porcine skin is said to be a closer 
representation of permeation through human skin [30], [65].  
 
Within the chemical category of FAs, oleic acid is one of the most widely studied 
chemical permeation enhancers. Francoeur et al. studied the effects of oleic acid on porcine 
SC via DSC analysis. Their results showed that OA markedly decreased the phase 
transition temperatures of SC lipids. They suggested that OA must mainly carry out its 
effect by disrupting SC lipids since no keratin denaturation was observed within these 
studies [66]. Past studies have suggested that OA is able to act by incorporating itself into 
the lipid lamellae of the SC with its polar end aligning with the polar heads of the lipids. It 
is thereby able to break associations between lipid polar groups and disrupt cholesterol 
stiffened regions leading to lipid fluidization [11]. Ex vivo penetration studies were 
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recently conducted on human skin using time-of-flight secondary ion mass spectrometry 
(TOF-SIMS) bioimaging to visualize and analyze distribution of OA in skin sections. This 
study suggested that OA may participate in the formation of regions of increased fluidity 
within the SC. Interestingly, OA was also seen to permeate into both the epidermal and 
dermal layers of the skin [67].  
 
The mechanism of action behind the enhanced permeation seen with the addition 
of fatty acids is generally thought to be caused by a disruption of the densely packed SC 
lipids leading to fluidization. For saturated FAs, optimal chain lengths of 10-12 carbons 
also correspond to the dimensions of the cholesterol skeleton found within the intercellular 
space of the SC. It was therefore proposed that disruption of ceremide-cholesterol or 
cholesterol-cholesterol interactions may play an important role in the mechanistic action 
of such FAs [65]. The double bonds found within unsaturated FAs have been shown to 
form kinks in the SC lipid structure. These kinks allow such FAs to create separate domains 
within the intercellular lipid lamellae. This structural change may either decrease the 




Surfactants are amphipathic molecules that contain a hydrophobic (lipophilic alkyl 
or aryl fatty chain) tail connected to a hydrophilic (polar) head group. Surfactants are 
classified according to their polar head groups. Possible categories include anionic 
surfactants (negatively charged head group), cationic surfactants (positively charged head 
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group), non-ionic surfactants (uncharged head group), and zwitterionic surfactants (both 
positively and negatively charged head group) (Figure 8) [68]. 
 
Figure 8: Schematic of various types of surfactants. Adapted from Malmsten M. 2002. [68]  
Depending on the size of each portion, surfactants may present different solubility 
profiles. For example, if the hydrophobic segment is large, the surfactant will not be water-
soluble. If the hydrophobic segment is comparatively smaller, the surfactant will be soluble 
but contact between the hydrophobic tail and the aqueous medium will still be energetically 
unfavorable. Therefore, surfactant molecules will tend to accumulate at various interfaces 
such that water contact may be reduced. Surfactants also exhibit the ability to self-assemble 
into structures that allow reduced water contact. In such situations, the hydrophobic 
domains of the surfactant molecules associate to form structures such as micelles or 
microemulsions. The formation of such structures give rise to a number of advantages i.e., 
through solubilization in the core of micelles the effective solubility of a hydrophobic drug 
may be increased, its hydrolytic degradation decreased, and its bioavailability improved 
[68].  
 
Anionic surfactants include carboxylates, sulfates, sulfonates, and phosphate esters. 
Such surfactants tend to permeate slowly through the SC but permeation is seen to increase 
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with extended exposure [69]. One of the most well-studied anionic surfactants is the alkyl 
sulfate sodium lauryl sulfate (SLS). To explain their mechanism of action, Ribaud et al. 
studied the effects of SLS on the organization of the SC. Their DSC results showed that 
SLS led to a decrease in the phase transition temperature of the SC lipid lamellae when 
used above a critical micellar concentration. They found that these effects were reversible 
after prolongated rinsing and therefore concluded the SLS disorganized but did not extract 
SC lipids [70]. Shokri et al. studied the effects of SLS in enhancing the permeation of 
diazepam through rat skin. They proposed that hydrophobic interactions between the SLS 
alkyl chain and the SC would leave the polar sulfate head group of the surfactant exposed. 
This would create additional water binding sites in the membrane leading to increased skin 
hydration and thereby increased drug flux [71]. It has been noted though that extended 
treatment of skin with anionic surfactants such as SLS leads to irreversible damage 
including protein denaturation, membrane expansion, and loss of water binding capacity 
[69]. 
 
Cationic surfactants are known to be more effective permeation enhancers than 
anionic surfactants, but they are also known to be more damaging towards skin [30], [72]. 
Cationic surfactants have been shown to interact with skin via both polar interactions and 
hydrophobic binding [69]. Fang et al. studied the effects of various surfactants on the 
transdermal delivery of enoxacin. Their results demonstrated that cationic surfactants, such 
as benzalkonium chloride (BKC), increased the permeation of enoxacin by disrupting 
intracellular keratin proteins [72]. Moghadam et al. found that cationic surfactants, such as 
didecyldimethylammonium bromide (DDAB), didecyltrimethylammonium bromide 
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(DTAB), and BKC severely disrupted the lateral organization of the SC. Their wide-angle 
X-ray scattering (WAXS) results showed decreased peak intensity suggesting that such 
surfactants destroyed OR packing of SC lipids [73]. 
 
Non-ionic surfactants are less damaging towards skin, but they have also been 
found to be less effective as CPEs. Examples of such CPEs include Tween 20, Tween 80, 
and polyoxyethylene alkyl ethers [30]. Three mechanisms of action have been proposed 
for non-ionic surfactants. They may penetrate into the intercellular region of the SC thereby 
increasing its fluidity. This can lead to the eventual solubilization and extraction of lipid 
components. Such surfactants may also interact with intracellular keratin filaments and 
their associated water molecules making such areas more aqueous. According to Shokri et 
al., Tween 80 is thought to enhance the penetration of diazepam via both of the 
aforementioned mechanisms [71]. A third mechanism proposed for non-ionic surfactants 
is by changing the thermodynamic activity of the drug through emulsification of sebum. 
[69].  
 
Zwitterionic surfactants include examples such as dodecylbetaine, 
hexadecylbetaine, hexadecylsulfobetaine, N, N–dimethyl–N-dodecyl amine oxide, 
dodecyltrimethylammonium bromide. Such surfactants are known to increase permeation 






Transcutol is a diethylene glycol monoethyl ether (DEGEE) that exists as a 
hygroscopic liquid. It is able mix readily with both polar and non-polar solvents. This 
excipient offers advantages over other enhancers as it is clear (transparent), non-volatile, 
and nearly odorless. There are currently three brands of Transcutol on the market today: 
Transcutol CG, Transcutol P, and Transcutol HP. Transcutol has been shown to enhance 
the permeation of a number of drugs including clonazepam, ketoprofen, dorzolamide 
hydrochloride, piroxicam, indomethacin, amlodipine, nitrendipine, and quercetin [74], 
[75].  
 
Godwin et al. studied the effects of Transcutol CG on the transdermal permeation 
of two UV absorbers, oxybenzone and cinnamate. Their in vitro permeation studies on 
hairless mice skin showed the Transcutol increased skin accumulation of oxybenzone and 
cinnamate while decreasing overall transdermal permeation. Similar accumulation results 
were seen with hydrocortisone and dexamethasone when mixed with saturated Transcutol 
solutions. The mechanism behind this accumulation is termed “intracutaneous depot.” It 
was proposed that Transcutol caused swelling of the SC intercellular lipids without altering 
its multi-lamellar structure. The swollen lipids were then able to retain drugs (especially 
lipophilic compounds), forming a depot. The data from Godwin et al., study are consistent 
with the aforementioned theory in that application of increasing concentrations of 
Transcutol lead to increased accumulation of the UV absorbers without a simultaneous 




Arora et al. studied the effects of Transcutol P as a cosurfactant in nanoemulsion-
based hydrogels for the transdermal delivery of ketoprofen. Contrary to the study done by 
Godwin et al., the results of this ex vivo permeation study on rat skin showed that a lack 
of Transcutol P within the formulation led to increased skin retention and lag time of 
ketoprofen within the SC. The addition of Transcutol P rather played a significant role in 
enhancing the permeation of ketoprofen. The CPE’s mechanism of action was thought to 
result from the solvation of intracellular α-keratin and occupation of proteinaceous 
hydrogen binding both of which led to a cumulative increase in the permeation of 
ketoprofen [77].  
 
In a recent review, Osborne and Musakhanian proposed an explanation for the 
discrepancies seen across studies regarding Transcutol’s ability to enhance vs retard drug 
flux. They suggested that as a solvent, Transcutol can significantly increase a drug’s 
solubility within the SC which subsequently influences the drug’s thermodynamic driving 
force. It is when this thermodynamic activity is not considered that Transcutol may appear 
to retard rather than enhance skin penetration [75]. In support of this claim, Bialik et al. 
showed that ibuprofen, when fully dissolved in Transcutol, did not produce measurable 
flux across human skin [78]. But when the formulation was diluted with water an increase 
in permeation was noted. Ibuprofen solubility in Transcutol is significantly higher than in 
water. The author of the study explained that with the addition of water, an increasing 
amount of ibuprofen falls out solution, creating a higher thermodynamic activity which 




The ability of Transcutol to act as a powerful solubilizing agent was also suggested 
by multiple studies to be due to its primary mechanism of enhancing drug flux. Mura et al. 
studied the effects of Transcutol on the flux of clonazepam from hydrophilic gel 
formulations. The results of in vitro permeation experiments showed that Transcutol 
primarily acted as a cosolvent, increasing permeation of clonazepam by increasing its 
solubility and therefore its concentration gradient in solution. A similar mechanism was 
proposed for the Transcutol-enhanced permeation for thymoquinone across human cadaver 
skin. [38], [44]. It is worth noting that by solubilizing drug molecules, Transcutol is also 
able to decrease the charge on ionized drugs, a mechanism known as the ‘solvent effect’. 
According to this effect, anytime a liquid with a dielectric constant lower than the dielectric 
constant of water (ɛ = 78) is added to an aqueous solution of ionized drug, the solvent can 
preferentially solvate the drug and prevent it from completely ionizing by forming ion pairs 
in the low dielectric medium. This decrease in drug charge can significantly increase the 
amount of unionized drug partitioning into and through the skin [75].  
 
An alternative mechanism of action was proposed by Moghadam et al. who 
studied the effects of Transcutol P on permeation of interferon-alpha. Their SAXS and 
WAXS studies suggested that Transcutol created a disordering effect within the SC 
membrane. This overall change in membrane disorder generally correlates to a 
disturbance of the crystalline packed lateral structures of the SC lipids, i.e., changes from 
their natural OR arrangement to a HEX or LIQ phase. These shifts have previously been 
reported to improve the permeability of molecules and was therefore attributed to 
Transcutol’s mechanism of action in this study [73].  
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FUTURE OUTLOOK ON CHEMICAL PERMEATION ENHANCERS 
 
As can be seen from the previous section, most CPEs exert their effects by 
disrupting the SC barrier in one way or another. Ideally, these effects would be reversible 
and localized to the non-viable layers of the SC but that is not always the case. CPEs run 
the risk of eventually affecting viable epidermal cells which may cause irritation by 
triggering the interstitial release of cytokines or other inflammatory processes [79]. 
 
With fatty acids, erythema and edema have been reported after cutaneous 
administration of lauric acid, palmitic acid, myristic acid, stearic acid, or oleic acid in 5 % 
(w/v) alcohol solutions. Follicular epidermal hyperplasia due to oleic acid and thinning of 
collagen fibers by myristic acid have also been seen. [80]. With respect to fatty alcohols, 
Kanikkannan et al. found that lauryl alcohol caused worsened irritation, as indicated by 
erythema of skin, than myristyl alcohol, tridecanol, decanol, undecanol, nonanol, and 
octanol [46]. The use of ethanol in topical formulations has been seen to cause skin 
irritation or contact dermatitis. But it is worth noting that ethanol is usually used in 
combination with other chemicals and it has therefore been difficult to conclusively 
attribute the irritation seen to ethanol alone [81]. Alternatively, PG has not been found to 
be a skin sensitizer, causing little to no skin irritation upon application [82]. Application of 
Azone has been seen to increase the number of neutrophils and lymphocytes within the 
epidermis indicating the triggering of an inflammatory response in the superficial layers of 
the skin [83]. Azone has also been found to cause erythematous plaques upon application 
to the skin, although the same study concluded that the effects were minimal and that Azone 
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was generally well tolerated amongst patients [84]. Surfactants are considered one of the 
most damaging CPEs with respect to the skin irritation they have been shown to invoke. 
Ionic surfactants are much more irritating that nonionic surfactants which are generally 
recognized as safe. The level of irritation with surfactants has also been shown to worsen 
with increased time-span of application [69].  
 
Despite the array of studies showing skin irritation as a likely side effect for most 
CPEs, they are still valued due to their ease of use and affordable production. For this 
reason, researchers have been keen on finding ways to work around the potential for skin 
irritation. One proposed method for doing so is to combine multiple CPEs. Whereas 
individual CPEs may cause irritation to the skin, such effects have been seen to be reduced 
with synergistic use of CPEs. For example, Narishetty et al., conducted histological 
evaluations of human skin after exposing it to oleic acid and menthol. With application of 
5% w/w menthol or 5% wt/wt oleic acid, skin irritation was indicated by slight to marked 
sub-epidermal oedema and swelling in collagen fibers. But the observed irritation was 
found to be much less with formulations combining menthol and oleic acid at 2.5% wt/wt 
[85].  
 
Karande et al. tested 32 individual CPEs and did not find anyone that achieved 
therapeutic levels of macromolecule skin permeability without causing irritation. They 
therefore set out on a search for a new family of permeation enhancers which they 
designated synergistic combinations of penetration enhancers (SCOPE). In order to create 
a library of SCOPE candidates, the researchers randomly paired CPEs from various 
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categories (surfactants, fatty acids, fatty esters, Azone, etc.) which led to the creation 496 
binary CPE pairs. For each pair, 44 distinct chemical compositions were created with the 
concentration of each CPE ranging from 0–2% (wt/vol), yielding a library of ∼25,000 
candidate SCOPE formulations. They then went on to test 20% (5,040 formulations) of this 
library through in vitro skin impedance guided high-throughput (INSIGHT) screening. 
Formulations were screened for enhancement potential measured in terms of enhancement 
ratios (ER) as well as for irritation potential (IP). The results of the INSIGHT screening 
are shown in Figure 9 where ER-IP data are plotted across four quadrants [79].  
 
Figure 9: A plot of the IP versus ER for selected enhancers (red circle, individual enhancers; green circle, 
enhancer mixtures). Adapted from Karande et al. [79] 
In Figure 9, quadrant I corresponds to safe but weak enhancers, quadrant II corresponds to 
weak and irritating enhancers, quadrant III corresponds to potent and irritating enhancers 
and quadrant IV corresponds to potent and safe enhancers. Most single CPEs were located 
in quadrants I or II (red circles). However, a substantial number of leading hits from the 
INSIGHT screening (green circles) were located in quadrant IV, meaning they were found 
to be both potent and safe! It is also worth noting that for single enhancers, IP increased 
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proportionally with ER. This gives credence to the fact that it is very difficult, if not 
impossible, to design a potent yet non-irritating formulation for TDDS using a single 
enhancer [79]. 
 
TDDS centered around the use CPEs have long been sought out due to their 
affordable nature and simplicity of use. Many chemical classes of enhancers have been 
developed and thoroughly studied. While almost every class of CPE has been shown to 
modify the SC such that drug flux can be increased, two significant disadvantages persist. 
First, side effects such as skin irritation seem to be unavoidable with increased potency of 
a given enhancer. And second, the upper limit of a CPEs efficacy remains intrinsically 
linked to the molecular weight (MW) of the drug being delivered i.e., most successful CPEs 
have been known to deliver drugs with MWs < 500 Da [86]. The future of CPEs therefore 
relies on the ability to tune their characteristics such that these disadvantages may be 
addressed.  
 
As discussed, the synergistic activity of CPE pairs may be the answer to 
overcoming the limitation of increased skin irritation seen with effective enhancers. In the 
past, the design of synergistic systems was limited by the low throughput of experimental 
screening methods [87]. Now, through advanced screening systems like INSIGHT, we may 
be able to find a new category of chemical enhancers that are increasingly potent without 
a subsequent increase of skin irritation. The need for formulations capable of enhancing 
the diffusion of large MW drugs may also be addressed by a relatively new chemical class 
of enhancers called ionic liquids (IL). ILs are organic salts composed of large asymmetric 
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cations paired to anions. Studies by Qi and Mitragotri have shown that ILs such as 1:2 
Choline:Geranic acid (CAGE) can enhance the transport of macromolecules up to 150 Da. 
Past studies have also observed an increase in the flux of proteins, siRNA, and 
polysaccharides secondary to the addition of ILs [86]. Additionally, according to studies 
by Tanner et al., slight modifications to the ion pairs comprising ILs can lead to significant 
changes in the chemical properties of such enhancers making them extremely tunable [88]. 
This allows ILs to be modified to present favorable characteristics such as minimal skin 
irritation while retaining maximal efficacy [88].  
 
A thorough understanding of the mechanistic behavior of both synergistic CPE 
pairs and ILs is still in its infancy. Thus, we are only in the shadows of the full the potential 
of TDDS. With the use of novel permeation enhancers, such as those discussed, we may 
soon find ourselves with a drug delivery system that affords all the benefits of transdermal 
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